Status:
COMPLETED
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Lead Sponsor:
Centro Medico Nacional La Raza, IMSS
Collaborating Sponsors:
Universidad de La Frontera
Conditions:
Alcohol Withdrawal Delirium
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The cessation of alcohol consumption of people suffering from alcohol abuse frequently leads to the development of an alcohol withdrawal syndrome (AWS). The ethylic suppression syndrome is defined as...
Detailed Description
Alcohol withdrawal syndrome AWS (Alcohol Withdrawal Syndrome), is defined as the appearance of two or more data of autonomic hyperactivity, nausea, hallucinations and seizures associated with cessatio...
Eligibility Criteria
Inclusion
- Patients who received dexmedetomidine during their Emergency stay
- Patients who received diazepam during their Emergency stay
- CIE-10 codes consistent with alcohol withdrawal during hospitalization
- CIWA-A score \>10 points
Exclusion
- comorbid disease, including several with CNS trauma or cerebrovascular accidents, one with end-stage metastatic carcinoma, and one patient with severe sepsis.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03877120
Start Date
November 1 2017
End Date
August 31 2018
Last Update
March 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nayely Garcia Mendez
Mexico City, Mexico, 4780000